Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | OGG1 | O15527 | 1/20 | 0.30 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13358870 | 0.88 | HSD11B1 (0.35) | KDM4EHSD11B1MEN1KMT2AHTT | |
| SCHEMBL13358901 | 0.84 | HSD11B1 (0.35) | HSD11B1MEN1KMT2APARP1BCHE | |
| SCHEMBL4702284 | 0.81 | HSD11B1 (0.37) | HSD11B1MEN1KMT2APARP1BCHE | |
| SCHEMBL12480051 | 0.80 | HSD11B1 (0.36) | HSD11B1MEN1KMT2APARP1BCHE | |
| SCHEMBL13358906 | 0.78 | HSD11B1 (0.37) | KDM4EHSD11B1MEN1KMT2AHTT | |
| SCHEMBL9003830 | 0.72 | PARP1 (0.46) | KDM4ETDP1HSD11B1MAPTPOLB | |
| SCHEMBL13358882 | 0.71 | NFKB1 (0.39) | KDM4EMEN1KMT2AMAPT | |
| SCHEMBL5742413 | 0.70 | HSD11B1 (0.36) | HSD11B1POLBPARP1BCHE | |
| SCHEMBL31384796 | 0.68 | CES2 (0.52) | TDP1MEN1KMT2AHTTPARP1 | |
| SCHEMBL9003690 | 0.68 | CES2 (0.52) | TDP1MEN1KMT2AHTTPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297112-B1 | PYRAZOLE COMPOUNDS AS CCR1 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2013-04-03 | — | — | EP | disclosed |
| US-8293917-B2 | Pyrazole compounds as CCR1 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20110230521-A1 | Pyrazole Compounds As CCR1 Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230521-A1 | Pyrazole Compounds As CCR1 Antagonists | CCR1, CCR3, CCR4 | KDM4E 4403/4885TDP1 1996/4885HSD11B1 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.